BIOGEN INC.
BIIB evidence brief
What we can confirm
- BioSniper Score:
- 8.7 / 10
- Market Cap:
- $31.40B
- Lead Asset:
- BIIB080 (Phase 3)
What it means
What to watch
Prepared research question
What matters most for BIIB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BIIB
Biogen Inc. (BIIB) is a biotechnology company historically focused on neurology, now diversifying into immunology, kidney disease, and ophthalmology, with approved products such as LEQEMBI for early Alzheimer's disease and a late-stage pipeline including dapirolizumab pegol for lupus.
Key risk: High debt burden
BioSniper Score
Based on 6 of 6 signals
Financial data as of Mar 31, 2026.
Tracking 14 pipeline candidates · 54 clinical trials · 6 catalysts · 7 FDA decisions for BIOGEN INC..
Biogen Inc. (BIIB) is a biotechnology company historically focused on neurology, now diversifying into immunology, kidney disease, and ophthalmology, with approved products such as LEQEMBI for early Alzheimer's disease and a late-stage pipeline including dapirolizumab pegol for lupus.
- Total revenue of $2,477.8M and net income of $319.5M as of 2026-03-31 [sec].
- Total debt of $12,577.0M as of 2026-03-31 [sec].
- LEQEMBI (lecanemab-irmb) is approved for early Alzheimer's disease, developed in partnership with Eisai [pipeline].
- Completed acquisition of RayThera Inc. in August 2026, adding multiple immunology assets [news · published 2026-08-06].
- Five upcoming Phase 3 readouts in lupus, transplant, and rare disease programs are expected to begin as soon as next quarter [news · published 2026-09-15].
What works
- Biogen raised its non-GAAP earnings guidance after strong commercial execution and a pivot toward growth products [news · published 2026-08-21].
- The company is diversifying beyond neurology into immunology, kidney disease, and ophthalmology, with a broader late-stage pipeline [news · published 2026-09-12].
- LEQEMBI is an approved anti-amyloid antibody for early Alzheimer's disease, providing a commercial product in a high-demand area [pipeline].
What to weigh
- Biogen faces ongoing declines in its legacy multiple sclerosis portfolio [news · published 2026-08-21].
- Total debt of $12,577.0M as of 2026-03-31 is substantial relative to revenue [sec].
- The acquisition of RayThera Inc. for up to $1 billion adds financial commitment with lead asset only entering Phase 1 [news · published 2026-06-17].
From the filings
Quoted directly from source documents.
Biogen raised non-GAAP earnings guidance after strong commercial execution and pivot toward growth products.
“In recent months, Biogen raised its non-GAAP earnings guidance after strong commercial execution and a pivot toward growth products helped counter ongoing declines in its legacy multiple sclerosis portfolio.”
News · August 21, 2026
Biogen is diversifying beyond neurology into immunology, kidney disease, and ophthalmology.
“Biogen (NASDAQ:BIIB) executives said the company is focused on diversifying beyond its historical neurology concentration, advancing a broader late-stage pipeline and managing expenses as it seeks to return to growth.”
News · September 12, 2026
LEQEMBI is an approved anti-amyloid antibody for early Alzheimer's disease.
“Pipeline Candidate: LEQEMBI Generic Name: LECANEMAB-IRMB Indication: early Alzheimer's disease Phase: Approved Mechanism of Action: Anti-amyloid antibody targeting amyloid-beta”
Biogen completed acquisition of RayThera Inc. in August 2026.
“Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology.”
News · August 6, 2026
Catalyst timeline
- 2026-10-22 · Phase2_Start — A randomized, double-blind, placebo-controlled MAD study with open-label extension to evaluate BIIB147 in adult ALS patients.
- 2026-11-16 · Phase3_Start — A Phase 3 study with open-label extension in pediatric participants to evaluate diroximel fumarate and dimethyl fumarate for relapsing MS.
- 2033-10-29 · Patent_Expiry · DIROXIMEL FUMARATE — Patent expiry for NDA211855.
- 2035-11-16 · Patent_Expiry · DIMETHYL FUMARATE — Patent expiry for NDA204063.
- 2036-03-04 · Patent_Expiry · NUSINERSEN SODIUM — Patent expiry for NDA209531.
- 2037-08-23 · Patent_Expiry · ZURANOLONE — Patent expiry for NDA217369.
Risks & what to watch (3)›
Key risks
- High debt burden — Total debt of $12,577.0M as of 2026-03-31 is significant relative to revenue [sec].
- Legacy MS portfolio decline — Ongoing declines in legacy multiple sclerosis portfolio are a structural challenge [news · published 2026-08-21].
- Acquisition integration risk — RayThera acquisition for up to $1B adds financial commitment with lead asset only in Phase 1 [news · published 2026-06-17].
What to watch
- Five upcoming Phase 3 readouts in lupus, transplant, and rare disease programs expected to begin as soon as next quarter [news · published 2026-09-15].
- Commercial traction of LEQEMBI for early Alzheimer's disease [pipeline].
- Progress of immunology pipeline following RayThera acquisition, with lead program now in Phase 1 [news · published 2026-08-06].
- Patent expirations for diroximel fumarate (2033-10-29), dimethyl fumarate (2035-11-16), nusinersen sodium (2036-03-04), and zuranolone (2037-08-23) [catalyst].
Sources: Catalysts · News · Pipeline · Generated October 13, 2026 · How we verify sources →
Run BIOGEN INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BIOGEN INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
Profitable (positive operating cash flow)
OCF $646M · Net income $320M · Debt/OCF 4.9×
Lead: Approved
14 candidates
6 upcoming, next in ~8d
0 buys · 2 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 3.4%
- Days to cover
- 3.2
- Shares short
- 4,475,470
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BIIB short interestGovernance
Frequently asked questions
What is the AI investment thesis for BIOGEN INC.?
Biogen Inc. (BIIB) is a biotechnology company historically focused on neurology, now diversifying into immunology, kidney disease, and ophthalmology, with approved products such as LEQEMBI for early Alzheimer's disease and a late-stage pipeline including dapirolizumab pegol for lupus.
What is BIOGEN INC.'s lead drug candidate?
BIOGEN INC.'s most advanced tracked candidate is BIIB080 (Phase 3) for Healthy Volunteer.
What is BIOGEN INC.'s next catalyst?
BIOGEN INC.'s next tracked catalyst is a Phase2_Start event — "Phase2_Start: A Randomized, Double-Blind, Placebo-Controlled MAD Study With Open-Label Extension to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BIIB147 Administered Intrathecally to Adult Participants With ALS" — expected October 22, 2026.
Who is the CEO of BIOGEN INC.?
Mr. Christopher A. Viehbacher is the chief executive officer of BIOGEN INC. (BIIB).
Where is BIOGEN INC. headquartered?
BIOGEN INC. (BIIB) is headquartered in Cambridge, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.